Innovative prostate cancer treatment shows ‘remarkable’ results | The IndependentNotifications can be managed in browser preferences.Jump to contentIndependentSwipe for next articleIndependent Bulletin homepageDownload ourSocial PartnerWe are 8 logo (opens in a new tab)AllNewsSportCultureLifestyleElla PickoverSaturday 28 February 2026 03:00 GMTMyths about Prostate Cancer: Symptoms and TreatmentEarly-stage trials of a new immunotherapy drug, VIR-5500, for advanced prostate cancer have yielded "remarkable" results.The drug, a "T-cell engager," employs a unique "cloaking device" that ensures it only activates upon reaching the tumour site, significantly reducing adverse reactions.In trials involving 58 men with advanced prostate cancer resistant to other treatments, 45 per cent of 11 patients experienced tumour shrinkage.A high proportion of patients (88 per cent) reported only mild side effects, addressing a key challenge faced by traditional immunotherapies for prostate cancer.Researchers are optimistic that VIR-5500 could offer a new treatment option and potentially lead to a cure for advanced prostate cancer in the future.In fullNew prostate cancer drug showing ‘remarkable’ results during clinical trialThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in